Pharma BD Deal Intelligence
Cadbury Schweppes's $4.2B cash purchase of Pfizer's Adams unit (Halls, Trident, Dentyne, Chiclets) made it the world's #1 confectioner and beat its return-on-capital target a year early, but the gum category it bet on later shrank—Mondelez offloaded the developed-market gum brands in 2022 for roughly a third of what Cadbury alone had paid two decades earlier.
Adams made Cadbury the world's largest confectioner and hit its return targets early, but two decades on the gum category it bought into structurally shrank, and the brands were eventually sold off for a fraction of relevance.
Full analysis, sources & comparables →Investec's Michael Landymore called it 'a reasonable price, and a good strategic move,' though Euromonitor flagged Adams' 40% Latin America revenue…
Cadbury Schweppes acquired 100% of Adams from Pfizer for $4.2B cash (including $450M of expected tax benefits); the divestiture was tied to Pfizer's Pharmacia…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Cadbury Schweppes acquired the Adams confectionery business -- including the Halls, Trident, Dentyne, and Chiclets brands -- from Pfizer for $4.2 billion in cash. Pfizer divested the unit as part of its Pharmacia integration and consumer-health rationalization, while the acquisition vaulted Cadbury Schweppes to the world's number-one confectionery position with roughly 10% global share and long-sought U.S. scale.
Adams made Cadbury the world's largest confectioner and hit its return targets early, but two decades on the gum category it bought into structurally shrank, and the brands were eventually sold off for a fraction of relevance.
Assessment window: 15yr post-close.
$1.9B Adams 2001 net sales
Functional confectionery sits at the border of consumer packaged goods and OTC consumer health: medicated throat lozenges (Halls) provide menthol/eucalyptus-based throat soothing; sugar-free gum (Trident, Dentyne Ice) is positioned for dental health; breath mints (Clorets, Certs) target halitosis. Adams was Pfizer's heritage Warner-Lambert consumer franchise inherited via the 2000 merger.
At the time of the 2003 deal, the global gum and functional confectionery category was led by Wrigley (Orbit, Extra, Eclipse, ~50% global gum share) with Adams a clear #2 (~25%) anchored by Trident, Dentyne Ice, and the Bubbas line. In medicated throat lozenges, Halls was the dominant US/global brand, competing with Reckitt Benckiser's Strepsils, J&J's Sucrets, and private label. In broader confectionery, Mars/Wrigley, Nestle, Hershey, and Ferrero were the principal scale players. The deal made Cadbury Schweppes the world's #1 confectionery company by value with a ~10% share, surpassing Mars and Nestle, and gave it a credible US scale platform for the first time. For Pfizer, the divestiture was driven by the Pharmacia integration (which itself brought Sudafed, Visine, and Listerine consumer health assets) and FTC requirements; Pfizer ultimately exited consumer health entirely with the 2006 sale of Pfizer Consumer Healthcare to J&J for $16.6B. Bidders Nestle and Kraft also pursued Adams, and the $4.2B price (including $450M tax-benefit value) was viewed by analysts as full but defensible — Investec's Michael Landymore called it 'a reasonable price and a good strategic move,' while Euromonitor flagged Latin America concentration risk (40% of Adams 2001 sales) and declining sugar-gum trends. Cadbury projected $60M+ in incremental annual operating profit by 2006 and $100M+ in cost synergies. Sources: https://www.confectionerynews.com/Article/2002/12/17/Cadbury-becomes-world-leader-with-Adams-acquisition/
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cadbury Schweppes plc / Adams Confectionery (Pfizer division) (this deal) | 2003 | $4.2B | 67 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Genzyme Corporation / SangStat Medical Corporation | 2003 | $600M | 78 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| IDEC Pharmaceuticals Corporation / Biogen Inc. | 2003 | $6.5B | 77 |
| Johnson & Johnson / Crucell NV | 2003 | $2.4B | 75 |
← Browse all deals · How we score deals
More: 2003 deals